Clinical Study
Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease
Table 2
Metabolic features of patients before and 6
months after rosiglitazone treatment. Values are mean ± SD.
| |||||||||||||||||||||||||||||||||||||||||||||||||
*
compared to baseline; # compared to baseline. |